BRPI0804070A2 - usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produto - Google Patents
usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produtoInfo
- Publication number
- BRPI0804070A2 BRPI0804070A2 BRPI0804070-2A BRPI0804070A BRPI0804070A2 BR PI0804070 A2 BRPI0804070 A2 BR PI0804070A2 BR PI0804070 A BRPI0804070 A BR PI0804070A BR PI0804070 A2 BRPI0804070 A2 BR PI0804070A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- anaplastic lymphoma
- lymphoma kinase
- product
- acid molecule
- Prior art date
Links
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 title abstract 6
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001162—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96041407P | 2007-09-28 | 2007-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0804070A2 true BRPI0804070A2 (pt) | 2009-09-29 |
Family
ID=40283936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0804070-2A BRPI0804070A2 (pt) | 2007-09-28 | 2008-09-26 | usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produto |
Country Status (5)
Country | Link |
---|---|
US (2) | US8980287B2 (pt) |
EP (1) | EP2042191B1 (pt) |
BR (1) | BRPI0804070A2 (pt) |
CA (1) | CA2640655A1 (pt) |
IL (1) | IL194388A0 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8383793B2 (en) * | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
BR112015018418A2 (pt) | 2013-02-22 | 2017-07-18 | Hoffmann La Roche | métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico |
AU2015243241A1 (en) * | 2014-04-10 | 2016-11-03 | Memorial Sloan-Kettering Cancer Center | A novel isoform of Anaplastic Lymphoma Kinase and its uses |
US11623002B2 (en) * | 2016-01-29 | 2023-04-11 | Elicio Therapeutics, Inc. | ALK polypeptides and methods of use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2002042232A1 (ja) | 2000-11-22 | 2004-03-25 | 旭硝子株式会社 | カラー陰極線管およびカラー陰極線管用ガラスフリット |
US20030157101A1 (en) * | 2001-11-15 | 2003-08-21 | Carlo Gambacorti-Passerini | Immunogenic ALK peptides |
-
2008
- 2008-09-23 EP EP08164900A patent/EP2042191B1/en not_active Not-in-force
- 2008-09-25 US US12/237,787 patent/US8980287B2/en active Active
- 2008-09-25 IL IL194388A patent/IL194388A0/en unknown
- 2008-09-26 BR BRPI0804070-2A patent/BRPI0804070A2/pt not_active IP Right Cessation
- 2008-09-26 CA CA002640655A patent/CA2640655A1/en not_active Abandoned
-
2015
- 2015-03-16 US US14/658,774 patent/US9650614B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9650614B2 (en) | 2017-05-16 |
US20150232820A1 (en) | 2015-08-20 |
US20090118216A1 (en) | 2009-05-07 |
IL194388A0 (en) | 2011-08-01 |
CA2640655A1 (en) | 2009-03-28 |
EP2042191A1 (en) | 2009-04-01 |
US8980287B2 (en) | 2015-03-17 |
EP2042191B1 (en) | 2013-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
BR112019000598A2 (pt) | rna para terapia de câncer | |
BR112015025711A8 (pt) | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer | |
BRPI0612845A8 (pt) | composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador | |
BRPI0916235A2 (pt) | composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv | |
BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
BRPI0817503B8 (pt) | derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa | |
BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
BRPI0622054B8 (pt) | composto e composição farmacêutica | |
BR112015011171A2 (pt) | compostos de pirrolopirimidina como inibidores da quinase | |
MX341591B (es) | Inhibidores de cinasa de benzoxazol y metodos de uso de los mismos. | |
ECSP088350A (es) | Pirazolopirimidinas como inhibidores de protein quinasas | |
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
BR112015010059A2 (pt) | terapia adjuvante com inibidor da quinase da família tec | |
BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
CL2008002381A1 (es) | Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer. | |
CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
WO2010006086A3 (en) | Kinase inhibitors and methods of use | |
BRPI0717845A2 (pt) | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos | |
CL2010001538A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular. | |
BR112013006395A2 (pt) | moduladores do receptor de estrogênio e seus usos. | |
BR112016008010A2 (pt) | uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose | |
CR20120490A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO. |
|
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: ANULADA A EXIGENCIA PUBLICADA NA RPI 2004 DE 02/06/2009, POR MOTIVO DE A MESMA TER SIDO INDEVIDA. |
|
B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 3A ANUIDADE. |